Biotech and Pharmaceuticals Pharmaceuticals

More

  • July 21- Biogen Inc's quarterly adjusted profit blew past Wall Street estimates on higher sales of its multiple sclerosis drugs, and the company said Chief Executive George Scangos would leave in the coming months. Biogen's hemophilia drugs, Eloctate and Alprolix, posted sales of $125 million and $80 million, respectively, above estimates of $190 million.

  • July 21- Biogen Inc said on Thursday Chief Executive George Scangos will leave the U.S. drugmaker in the coming months and that its board approved a $5 billion share repurchase program. The company said total revenue rose about 12 percent to $2.47 billion in its second-quarter ended June 30. Net income attributable to the company rose to $1.05 billion, or $4.79...

  • NEW YORK— Biogen stock climbed Thursday after the drugmaker reported strong sales of some of its newest treatments for multiple sclerosis and hemophilia. In Thursday morning trading the shares gained $15.92, or 6.1 percent, to $278.33. The company said its net income grew to $1.05 billion, or $4.79 per share.

  • Crucial UK builds effective regulatory system: Roche CEO

    Roche CEO, Severin Schwan explains why the impact of Brexit on the pharmaceutical firm is "rather limited".

  • Very pleased with results: Roche CEO

    Severin Schwan, CEO of Roche, discusses the highlights from the company's earnings results for the first half of 2016.

  • It has been a very good performance: Actelion CEO

    Jean-Paul Clozel, CEO of Actelion, discusses the company's latest earnings results and discusses the pharma sector.

  • *Digitally connected devices aim to track medicine use. LONDON, July 20- Makers of inhalers to treat asthma and chronic lung disease are racing to develop a new generation of smart devices with sensors to monitor if patients are using their puffers properly. GlaxoSmithKline, AstraZeneca and Novartis are all chasing the opportunity via deals with device firms...

  • Democratic Presumptive Nominee for President former Secretary of State Hillary Clinton.

    Strategas Research Partners analyzed the important 2016 political events for the drug and pharma industry.

  • District Judge Randolph Moss in Washington, D.C. ruled that AstraZeneca was not likely to win a lawsuit claiming it should get seven more years of exclusive rights to the drug thanks to its recent approval to treat a rare pediatric illness. Crestor, which accounted for more than 20 percent of AstraZeneca's $23.6 billion in sales last year, was approved by the FDA...

  • FDA panel backs approval for Valeant's psoriasis drug

    U.S. FDA panel backs Valeant psoriasis drug with risk management. CNBC's Meg Tirrell reports.

  • Shares of the diversified healthcare products maker rose 1.6 percent at $125.06 on the New York Stock Exchange after touching a new record high of $125.75. The company, which is the first major U.S. drugmaker to announce quarterly earnings, raised its 2016 sales forecast to a range of $71.5 billion to $72.2 billion, from $71.2 billion to $71.9 billion previously.

  • Shares of the diversified healthcare products maker rose 1.3 percent at $124.80 on the New York Stock Exchange after touching a new record high of $125.75. J&J, which is the first major U.S. drugmaker to announce quarterly earnings, raised its 2016 sales forecast to a range of $71.5 billion to $72.2 billion, from $71.2 billion to $71.9 billion previously.

  • Cramer's Mad Dash: J&J's earnings beat

    Jim Cramer explains what to watch ahead of the open, including the outlook for Johnson & Johnson.

  • Stocks to Watch: July 19, 2016

    Netflix, Goldman Sachs and Johnson & Johnson are making headlines this Tuesday morning.

  • J&J, which is the first major U.S. drugmaker to announce quarterly earnings, raised its 2016 sales forecast to a range of $71.5 billion to $72.2 billion, from $71.2 billion to $71.9 billion previously estimated. The maker of medical devices, drugs and personal care products also increased its adjusted profit range to $6.63- $6.73 per share, from $6.53- $6.68 per...

  • J&J, which is the first major U.S. drugmaker to announce quarterly earnings, raised its 2016 sales forecast to a range of $71.5 billion to $72.2 billion from $71.2 billion to $71.9 billion. However, the company's net earnings fell to $3.997 billion, or $1.43 per share, from $4.516 billion, or $1.61 per share. Analysts on average had expected a profit of $1.68 per share...

  • Surging second-quarter sales of Johnson& Johnson's prescription drugs, its healthiest business, were more than offset by a one-time gain a year ago, driving profit down 11.5 percent. But the health care giant easily beat Wall Street's expectations and raised its full-year financial forecasts. The world's biggest maker of health care products reported net...

  • ZURICH, July 19- Switzerland's Novartis, the world's biggest maker of prescription drugs, will continue to invest in Britain, despite the country's decision to leave the European Union, its chief executive said on Tuesday. "We will continue to invest strongly in the UK despite the decision to exit the EU as we see very large areas of unmet medical need and the...

  • GENEVA— Swiss pharmaceuticals company Novartis says its net profit fell 4 percent in the second quarter, largely because of new generic competition for its top cancer drug, though it expressed high hopes for a psoriasis drug that has turned out to be one of its best product launches ever. That will depend largely on the expected continued slide in sales for the...

  • These are America's 5 most expensive prescription drugs

    Prescription drug prices have soared, often exceeding US average annual income. These are the five most expensive.